

Edgar Filing: FONAR CORP - Form 10-Q

FONAR CORP
Form 10-Q
May 19, 2009

FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended MARCH 31, 2009

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission file number 0-10248

FONAR CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE

11-2464137

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

110 Marcus Drive, Melville, New York

11747

(Address of principal executive offices)

(Zip Code)

(631) 694-2929

Registrant's telephone number, including area code:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files): Yes ☐ No ☐

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the close of the latest practicable date.

Edgar Filing: FONAR CORP - Form 10-Q

Class	Outstanding at April 30, 2009
-----	-----
Common Stock, par value \$.0001	4,904,275
Class B Common Stock, par value \$.0001	158
Class C Common Stock, par value \$.0001	382,513
Class A Preferred Stock, par value \$.0001	313,451

FONAR CORPORATION AND SUBSIDIARIES
INDEX

PART I - FINANCIAL INFORMATION

PAGE

Item 1. Financial Statements

Condensed Consolidated Balance Sheets - March 31, 2009
(Unaudited) and June 30, 2008

Condensed Consolidated Statements of Operations for
the Three Months Ended March 31, 2009 and
March 31, 2008 (Unaudited)

Condensed Consolidated Statements of Operations for
the Nine Months Ended March 31, 2009 and
March 31, 2008 (Unaudited)

Condensed Consolidated Statements of Comprehensive
Income (Loss) for the Three Months Ended
March 31, 2009 and March 31, 2008 (Unaudited)

Condensed Consolidated Statements of Comprehensive
Income (Loss) for the Nine Months Ended
March 31, 2009 and March 31, 2008 (Unaudited)

Condensed Consolidated Statements of Cash Flows for
the Nine Months Ended March 31, 2009 and
March 31, 2008 (Unaudited)

Notes to Condensed Consolidated Financial Statements (Unaudited)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 4. Controls and Procedures

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Item 2. Changes in Securities

Item 3. Defaults Upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders

Item 5. Other Information

Edgar Filing: FONAR CORP - Form 10-Q

Item 6. Exhibits

Signatures

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (000's OMITTED)

ASSETS	March 31, 2009 (UNAUDITED)	June 30, 2008
Current Assets:	-----	-----
Cash and cash equivalents	\$ 1,605	\$ 1,326
Marketable securities	18	1,068
Accounts receivable - net	5,206	4,689
Accounts receivable - related parties - net	619	469
Medical receivables - net	555	1,228
Management fee receivable - net	4,051	5,040
Management fee receivable - related medical practices - net	1,480	1,372
Costs and estimated earnings in excess of billings on uncompleted contracts	528	6
Inventories	3,793	3,256
Current portion of advances and notes to related medical practices	193	214
Current portion of notes receivable less discount for below market interest	509	2,508
Prepaid expenses and other current assets	409	811
Total Current Assets	----- 18,966	----- 21,987
Property and equipment - net	3,152	3,933
Advances and notes to related medical practices - net	133	263
Notes receivable less discount for below market interest	1,912	2,297
Other intangible assets - net	4,896	4,810
Other assets	574	1,936
Total Assets	----- \$ 29,633 =====	----- \$ 35,226 =====

See accompanying notes to condensed consolidated financial statements (unaudited).

FONAR CORPORATION AND SUBSIDIARIES

Edgar Filing: FONAR CORP - Form 10-Q

CONDENSED CONSOLIDATED BALANCE SHEETS (000's OMITTED)

	March 31, 2009 (UNAUDITED)	June 30, 2008 -----
LIABILITIES AND STOCKHOLDERS' DEFICIENCY		
Current Liabilities:	-----	-----
Current portion of long-term debt and capital leases	\$ 141	\$ 373
Accounts payable	3,720	4,020
Other current liabilities	8,045	8,316
Unearned revenue on service contracts	5,045	4,732
Unearned revenue on service contracts - related parties	612	462
Customer advances	7,871	12,804
Customer advances - related party	854	1,472
Billings in excess of costs and estimated earnings on uncompleted contracts	5,133	5,773
	-----	-----
Total Current Liabilities	31,421	37,952
Long-Term Liabilities:		
Due to related medical practices	95	98
Long-term debt and capital leases, less current portion	746	757
Other liabilities	319	497
	-----	-----
Total Long-Term Liabilities	1,160	1,352
	-----	-----
Total Liabilities	32,581	39,304
	-----	-----
Minority interest	64	167
	-----	-----

See accompanying notes to condensed consolidated financial statements (unaudited).

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (000's OMITTED, except share data)

	March 31, 2009 (UNAUDITED)	June 30, 2008 -----
LIABILITIES AND STOCKHOLDERS' DEFICIENCY (continued)		
STOCKHOLDERS' DEFICIENCY:		
Class A non-voting preferred stock \$.0001 par value; 1,600,000 authorized, 313,451 issued and outstanding at March 31, 2009 and June 30, 2008	-	-
Common Stock \$.0001 par value; 30,000,000 shares authorized at March 31, 2009 and June 30, 2008, 4,915,918 issued at March 31, 2009 and June 30, 2008, 4,904,275 outstanding at March 31, 2009 and June 30, 2008	1	1
Class B Common Stock \$.0001 par value; 800,000 shares authorized, (10 votes per share), 158 issued and outstanding at March 31, 2009 and June 30, 2008	-	-
Class C Common Stock \$.0001 par value; 2,000,000 shares		

Edgar Filing: FONAR CORP - Form 10-Q

authorized, (25 votes per share), 382,513 issued
and outstanding at March 31, 2009 and June 30, 2008

	-	-
Paid-in capital in excess of par value	172,276	172,276
Accumulated other comprehensive loss	(25)	(73)
Accumulated deficit	(174,320)	(175,380)
Notes receivable from employee stockholders	(269)	(394)
Treasury stock, at cost - 11,643 shares of common stock at March 31, 2009 and June 30, 2008	(675)	(675)
	-----	-----
Total Stockholders' Deficiency	(3,012)	(4,245)
	-----	-----
Total Liabilities and Stockholders' Deficiency	\$ 29,633	\$ 35,226
	=====	=====

See accompanying notes to condensed consolidated financial statements
(unaudited).

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (000's OMITTED, except per share data)

	FOR THE THREE MONTHS ENDED MARCH 31,	
	2009	2008
REVENUES	-----	-----
Product sales - net	\$ 6,156	\$ 2,348
Service and repair fees - net	2,291	2,515
Service and repair fees - related parties - net	331	270
Management and other fees - net	1,736	2,110
Management and other fees - related medical practices - net	742	828
	-----	-----
Total Revenues - Net	11,256	8,071
	-----	-----
COSTS AND EXPENSES		
Costs related to product sales	3,325	2,237
Costs related to service and repair fees	865	1,148
Costs related to service and repair fees - related parties	125	123
Costs related to management and other fees	1,039	1,342
Costs related to management and other fees - related medical practices	686	751
Research and development	872	1,189
Selling, general and administrative	3,219	4,311
Provision (Credit) for bad debts	363	(309)
	-----	-----
Total Costs and Expenses	10,494	10,792
	-----	-----
Income (Loss) From Operations	762	(2,721)
Interest Expense	(75)	(105)
Investment Income	91	156
Interest Income - Related Parties	5	8
Other (Expense) Income	(17)	1
Minority Interest in Income of Partnerships	-	(34)
Provision for Income Taxes	(36)	-
	-----	-----
NET INCOME (LOSS)	\$ 730	\$ (2,695)
	=====	=====
Net Income (Loss) Available to Common Stockholders	\$ 686	\$ (2,695)

Edgar Filing: FONAR CORP - Form 10-Q

Basic Net Income (Loss) Per Common Share	\$ 0.14	\$ (0.55)
Diluted Net Income (Loss) Per Common Share	\$ 0.13	\$ (0.55)
Basic and Diluted Income Per Share - Common C	\$ 0.04	-
Weighted Average Basic Shares Outstanding	4,904,275	4,904,261
Weighted Average Diluted Shares Outstanding	5,031,779	4,904,261

See accompanying notes to condensed consolidated financial statements (unaudited).

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (000's OMITTED, except per share data)

FOR THE NINE MONTHS ENDED
MARCH 31,

	2009	2008
REVENUES		
Product sales - net	\$ 11,975	\$ 8,940
Service and repair fees - net	6,936	7,444
Service and repair fees - related parties - net	966	786
Management and other fees - net	5,518	6,354
Management and other fees - related medical practices - net	2,181	2,739
License fees and royalties	1,755	1,158
Total Revenues - Net	29,331	27,421
COSTS AND EXPENSES		
Costs related to product sales	7,590	8,566
Costs related to service and repair fees	2,696	3,546
Costs related to service and repair fees - related parties	376	375
Costs related to management and other fees	3,316	3,898
Costs related to management and other fees - related medical practices	2,040	2,241
Research and development	2,681	3,675
Selling, general and administrative	9,955	15,544
Provision for bad debts	1,063	279
Total Costs and Expenses	29,717	38,124
Loss From Operations	(386)	(10,703)
Interest Expense	(193)	(362)
Investment Income	236	531
Interest Income - Related Parties	17	27
Other (Expense) Income	(15)	7
Minority Interest in Income of Partnerships	(11)	(208)
Gain on Sale of Investment	-	571
Gain on Sale of Consolidated Subsidiary	1,448	3,395
Provision for Income Taxes	(36)	-
NET INCOME (LOSS)	\$ 1,060	\$ (6,742)

Edgar Filing: FONAR CORP - Form 10-Q

Net Income (Loss) Available to Common Stockholders	\$ 997	\$ (6,742)
	=====	=====
Basic Net Income (Loss) Per Common Share	\$ 0.20	\$ (1.38)
	=====	=====
Diluted Net Income (Loss) Per Common Share	\$ 0.19	\$ (1.38)
	=====	=====
Basic and Diluted Income per share - Common C	\$ 0.05	-
	=====	=====
Weighted Average Basic Common Shares Outstanding	4,904,275	4,895,907
	=====	=====
Weighted Average Diluted Common Shares Outstanding	5,031,779	4,895,907
	=====	=====

See accompanying notes to condensed consolidated financial statements (unaudited).

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (000'S OMITTED)

	FOR THE THREE MONTHS ENDED MARCH 31,	
	2009	2008
	-----	-----
Net income (loss)	\$ 730	\$ (2,695)
Other comprehensive (loss) income, net of tax:		
Unrealized (losses) gains on marketable securities, net of tax	(1)	12
	-----	-----
Total comprehensive income (loss)	\$ 729	\$ (2,683)
	=====	=====

See accompanying notes to condensed consolidated financial statements (unaudited).

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (000'S OMITTED)

	FOR THE NINE MONTHS ENDED MARCH 31,	
	2009	2008
	-----	-----
Net income (loss)	\$ 1,060	\$ (6,742)
Other comprehensive income, net of tax:		
Unrealized gains on marketable securities, net of tax	48	20
	-----	-----
Total comprehensive income (loss)	\$ 1,108	\$ (6,722)
	=====	=====

See accompanying notes to condensed consolidated financial statements

Edgar Filing: FONAR CORP - Form 10-Q

(unaudited) .

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (000'S OMITTED)

	FOR THE NINE MONTHS ENDED MARCH 31,	
	2009	2008
Cash Flows from Operating Activities:		
Net income (loss)	\$ 1,060	\$ (6,742)
Adjustments to reconcile net income (loss) to net cash used in operating activities:		
Minority interest in income of partnerships	11	208
Depreciation and amortization	1,297	1,727
Provision for bad debts	1,063	279
Stock issued for costs and expenses	-	205
Gain on sale of consolidated subsidiary	(1,448)	(3,395)
Gain on sale of investment	-	(571)
(Increase) decrease in operating assets, net:		
Accounts, management fee and medical receivable(s)	(1,093)	(3,351)
Notes receivable	385	424
Costs and estimated earnings in excess of billings on uncompleted contracts	(522)	-
Inventories	(537)	788
Prepaid expenses and other current assets	402	(196)
Other assets	(17)	(90)
Advances and notes to related medical practices	151	139
Increase (decrease) in operating liabilities, net:		
Accounts payable	(284)	(294)
Other current liabilities	192	1,780
Customer advances	(5,551)	4,729
Billings in excess of costs and estimated earnings on uncompleted contracts	(641)	113
Other liabilities	(178)	114
Due to related medical practices	(2)	-
Net cash used in operating activities	(5,712)	(4,133)

See accompanying notes to condensed consolidated financial statements
(unaudited) .

FONAR CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (000'S OMITTED)

	FOR THE NINE MONTHS ENDED MARCH 31,	
	2009	2008
Cash Flows from Investing Activities:		
Purchases of marketable securities	-	(765)
Sales of marketable securities	1,098	1,708
Purchases of property and equipment	(20)	(356)
Costs of capitalized software development	(392)	(426)
Cost of patents	(192)	(113)

Edgar Filing: FONAR CORP - Form 10-Q

Proceeds from note receivable	2,000	-
Proceeds from cash surrender value of life insurance	1,345	-
Proceeds from sale of investment	-	571
Proceeds from sale of consolidated subsidiary	2,293	4,142
	-----	-----
Net cash provided by investing activities	6,132	4,761
	-----	-----
Cash Flows from Financing Activities:		
Distributions to holders of minority interests	(23)	(117)
Proceeds from long-term debt	-	265
Repayment of borrowings and capital lease obligations	(243)	(200)
Repayment of notes receivable from employee stockholders	125	128
	-----	-----
Net cash (used in) provided by financing activities	(141)	76
	-----	-----
Net Increase in Cash and Cash Equivalents	279	704
Cash and Cash Equivalents - Beginning of Period	1,326	1,470
	-----	-----
Cash and Cash Equivalents - End of Period	\$ 1,605	\$ 2,174
	=====	=====

See accompanying notes to condensed consolidated financial statements (unaudited).

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION & LIQUIDITY & CAPITAL RESOURCES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended March 31, 2009 are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2009. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K filed on October 7, 2008 for the fiscal year ended June 30, 2008.

Liquidity and Capital Resources

In September 2008, the Company sold its 92.3% interest (to a related party) in an entity that provided management services to a scanning center in Bensonhurst, New York and received net cash proceeds of approximately \$2.3 million.

In August 2008, the Company signed a modification agreement with regards to the asset purchase agreement with Health Plus. The Company received a \$2,000,000

Edgar Filing: FONAR CORP - Form 10-Q

payment on the note issued by Health Plus.

At March 31, 2009, the Company had a working capital deficit of approximately \$12.5 million and a stockholders' deficiency of approximately \$3.0 million. For the nine months ended March 31, 2009, the Company generated net income of approximately \$1.1 million, which was due mainly to the improvement in the Company's operations and a gain of \$1.4 million from the sale of a consolidated subsidiary. The Company has funded its cash flow deficit for the nine months ended March 31, 2009 through cash provided by the sale of marketable securities and other assets discussed above. In addition, during June 2008, the Company implemented a restructuring program, including a reduction of its workforce, across the board salary reductions, elimination of manufacturing facilities and restructuring of its diagnostic imaging management service business. Management estimates that the annualized savings related to these cost-cutting measures approximates \$5,000,000.

Although sales levels remained weak in fiscal 2009, the Company has been profitable for two consecutive quarters and continues to focus its efforts on increased advertising and marketing campaigns, and distribution programs to strengthen the demand for its products and services. Management anticipates that its capital resources will improve if Fonar's MRI scanner products gain wider market recognition and acceptance resulting in increased product sales. If the Company is not successful with its marketing efforts to increase sales and weak demand continues, the Company will experience a shortfall in cash over the next twelve months. If necessary, the Company will implement its plan to fund such a deficit which includes further reductions in operating expenses, sales of certain assets and loans from related parties together in an amount sufficient to continue as a going concern through March 31, 2010. Current economic credit conditions have contributed to a slowing business environment. Given such liquidity and credit constraints in the markets, the business may suffer, should the credit markets not improve in the near future. The direct impact of these conditions is not fully known. However, there can be no assurance that the Company would be able to secure additional funds if needed and that if such funds were available, whether the terms or conditions would be acceptable to the Company. In such case, the further reduction in operating expenses might need to be substantial in order for the Company to generate positive cash flow to sustain the operations of the Company.

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the "Company"). All significant intercompany accounts and transactions have been eliminated in consolidation.

Earnings (Loss) Per Share

Basic earnings (loss) per share ("EPS") is computed based on weighted average shares outstanding and excludes any potential dilution. In accordance with EITF 03-6, "Participating Securities and the Two-Class method under FASB Statement No. 128" ("EITF 03-6"), the Company's participating convertible securities,

Edgar Filing: FONAR CORP - Form 10-Q

which include Class A Non-voting preferred stock, Class B common stock and Class C common stock, are not included in the computation of basic EPS for the nine months and three months ended March 31, 2008, because the participating securities do not have a contractual obligation to share in the losses of the Company. For the nine months and three months ended March 31, 2009, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share.

Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. The number of common shares potentially issuable upon the exercise of certain options and warrants or conversion of the participating convertible securities that were excluded from the diluted EPS calculation was approximately 278,000 because they were antidilutive as a result of net losses for the three and nine months ended March 31, 2008. For the three and nine months ended March 31, 2009, the number of common shares potentially issuable upon the exercise of certain options of 138,000 have not been included in the computation of diluted EPS since the effect would be antidilutive.

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Earnings (Loss) Per Share (Continued)

	Three months ended March 31, 2009	Three months ended March 31, 2008
	(000's omitted, except per share data)	
Basic	Total	Class C Common Stock
Numerator:		
Net income (loss) available to common stockholders	\$ 686	\$ 14
	=====	=====
Denominator:		
Weighted average shares outstanding	4,904	383
	=====	=====
Basic income (loss) per common share	\$ 0.14	\$ 0.04
	=====	=====
Diluted		
Denominator:		
Weighted average shares outstanding	4,904	383
Stock options	-	-
Warrants	-	-
Convertible Class C Stock	128	-
	-----	-----
Total Denominator for		

Edgar Filing: FONAR CORP - Form 10-Q

diluted earnings per share	5,032	5,032	383	4,904
	=====	=====	=====	=====
Diluted income (loss)				
per common share		\$ 0.13	\$ 0.04	\$ (0.55)
		=====	=====	=====

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Earnings (Loss) Per Share (Continued)

	Nine months ended March 31, 2009		Nine months ended March 31, 2008	
	(000's omitted, except per share data)			
		Common	Class C	
Basic	Total	Stock	Common	
		Stock	Stock	

Numerator:				
Net income (loss) available to common stockholders	\$ 997	\$ 977	\$ 20	\$ (6,742)
	=====	=====	=====	=====
Denominator:				
Weighted average shares outstanding		4,904	383	4,896
		=====	=====	=====
Basic income (loss) per common share		\$ 0.20	\$ 0.05	\$ (1.38)
		=====	=====	=====
Diluted				

Denominator:				
Weighted average shares outstanding	4,904	4,904	383	4,896
Stock options	-	-	-	-
Warrants	-	-	-	-
Convertible Class C Stock	128	128	-	-
	-----	-----	-----	-----
Total Denominator for diluted earnings per share	5,032	5,032	383	4,896
	=====	=====	=====	=====
Diluted income (loss) per common share		\$ 0.19	\$ 0.05	\$ (1.38)
		=====	=====	=====

Recent Accounting Pronouncements

In September 2006, the Financial Accounting Standard Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157, "Fair Value Measurements," ("SFAS 157"). This statement provides a single definition of fair value, a framework for measuring fair value, and expanded disclosures concerning

Edgar Filing: FONAR CORP - Form 10-Q

fair value. Previously, different definitions of fair value were contained in various accounting pronouncements creating inconsistencies in measurement and disclosures. SFAS 157 applies under those previously issued pronouncements that prescribe fair value as the relevant measure of value, except SFAS No. 123 (revised 2004), "Share-Based Payment", and related interpretations and pronouncements that require or permit measurement similar to fair value but are not intended to measure fair value. The Company adopted SFAS 157 on July 1, 2008, as required for its financial assets and financial liabilities. However, the FASB deferred the effective date of SFAS 157 for one year as it relates to fair value measurement requirements for nonfinancial assets and nonfinancial liabilities that are not recognized or disclosed at fair value on a recurring basis. The adoption of SFAS 157 for the Company's financial assets and financial liabilities did not have a material impact on its condensed consolidated financial statements. The Company is evaluating the effect the implementation of SFAS 157 for its nonfinancial assets and nonfinancial liabilities will have on the Company's condensed consolidated financial statements.

FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2009
(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)

Effective January 1, 2007, the Company adopted the provisions of FASB Interpretation No. 48, "Accounting of Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109" ("FIN 48"). FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as "unrecognized benefits". A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise's potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of FIN 48. In accordance with FIN 48, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as "Interest expense, net". Penalties if incurred would be recognized as a component of "General and administrative" expenses. The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2004. The adoption of the provisions of FIN 48 did not have a material impact on the Company's consolidated financial position and results of operations. As of March 31, 2009, no liability for unrecognized tax benefits was required to be recorded. The Company recognized a deferred tax asset of approximately \$76 million as of March 31, 2009, primarily related to net operating loss carryforwards of approximately \$165 million, available to offset future taxable income through 2028.

On February 15, 2007, the FASB issued SFAS No. 159, entitled "The Fair Value Option for Financial Assets and Financial Liabilities," ("SFAS 159"). The guidance in SFAS 159 "allows" reporting entities to "choose" to measure many financial instruments and certain other items at fair value. The objective underlying the development of this literature is to improve financial reporting

Edgar Filing: FONAR CORP - Form 10-Q

by providing reporting entities with the opportunity to reduce volatility in reported earnings that results from measuring related assets and liabilities differently without having to apply complex hedge accounting provisions, using the guidance in SFAS No. 133, as amended, entitled "Accounting for Derivative Instruments and Hedging Activities." The provisions of SFAS No. 159 are applicable to all reporting entities and are effective as of the beginning of the first fiscal year that begins subsequent to November 15, 2007. The Company adopted SFAS 159 effective July 1, 2008. Upon adoption, the Company did not elect the fair value option for any items within the scope of SFAS 159 and, therefore, the adoption of SFAS 159 did not have an impact on the Company's condensed consolidated financial statements.

FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2009
(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)

In March 2007, the FASB ratified the Emerging Issues Task Force ("EITF") consensus on EITF Issue No. 06-10. "Accounting for Collateral Assignment Split Dollar Life Insurance". This EITF indicates that an employer should recognize a liability for postretirement benefits related to collateral assignment split-dollar life insurance arrangements. In addition, the EITF provides guidance for the recognition of an asset related to a collateral assignment split-dollar life insurance arrangement. The EITF is effective for fiscal years beginning after December 15, 2007. The Company has adopted the EITF as required and it did not have an impact on the Company's results of operations, financial condition and liquidity.

In December 2007, the FASB issued SFAS No. 141R, "Business Combinations" ("SFAS 141R"), which replaces SFAS No. 141, "Business Combinations". SFAS 141R establishes principles and requirements for determining how an enterprise recognizes and measures the fair value of certain assets and liabilities acquired in a business combination, including noncontrolling interests, contingent consideration, and certain acquired contingencies. SFAS 141R also requires acquisition-related transaction expenses and restructuring costs be expensed as incurred rather than capitalized as a component of the business combination. SFAS 141R will be applicable prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. SFAS 141R would have an impact on accounting for any businesses acquired after the effective date of this pronouncement.

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements - An Amendment of ARB No. 51" ("SFAS 160"). SFAS 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary (previously referred to as minority interests). SFAS 160 also requires that a retained noncontrolling interest upon the deconsolidation of a subsidiary be initially measured at its fair value. Upon adoption of SFAS 160, the Company will be required to report its noncontrolling interests as a separate component of stockholders' equity. The Company will also be required to present net income allocable to the noncontrolling interest and net income attributable to the stockholders of the Company separately in its consolidated statements of income. Currently, minority interests are reported as a liability in the Company's consolidated balance sheets and the related income attributable to the minority interests is reflected as an expense in arriving at

Edgar Filing: FONAR CORP - Form 10-Q

net loss. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. SFAS 160 requires retroactive adoption of the presentation and disclosure requirements for existing minority interests. All other requirements of SFAS 160 shall be applied prospectively. The Company has adopted SFAS No. 160 and it did not have any impact on the Company's consolidated financial statements

FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2009
(UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)

In March 2008, the FASB issued SFAS No. 161, "Disclosures about Derivative Instruments and Hedging Activities—an amendment of FASB Statement No 133" ("SFAS No. 161"). SFAS No. 161 changes the disclosure requirements for derivative instruments and hedging activities. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS No. 133 and its related interpretations, and (c) how derivative instruments and related hedged item affect an entity's financial position, financial performance and cash flows. The guidance in SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. This Statement encourages, but does not require, comparative disclosures for earlier periods at initial adoption. The Company has adopted SFAS No. 161 and it did not have any impact on the Company's consolidated financial statements.

In May 2008, the FASB issued SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles". SFAS No. 162 identifies the sources of accounting principles and the framework for selecting the principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally accepted accounting principles in the United States. It is effective 60 days following the SEC's approval of the Public Company Accounting Oversight Board amendments to AU Section 411, "The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles". The adoption of this statement is not expected to have a material effect on the Company's consolidated financial statements.

In October 2008, the FASB issued FASB Staff Position No. FAS 157-3, "Determining the Fair Value of a Financial Asset in a Market That Is Not Active" ("FSP 157-3"), which clarifies the application of SFAS 157 when the market for a financial asset is inactive. Specifically, FSP 157-3 clarifies how (1) management's internal assumptions should be considered in measuring fair value when observable data are not present, (2) observable market information from an inactive market should be taken into account, and (3) the use of broker quotes or pricing services should be considered in assessing the relevance of observable and unobservable data to measure fair value. The guidance in FSP 157-3 is effective immediately and did not have a material impact on the Company's condensed consolidated financial statements.

FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2009
(UNAUDITED)

Edgar Filing: FONAR CORP - Form 10-Q

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Accounting Pronouncements (Continued)

In June 2008, the FASB ratified Emerging Issue Task Force ("EITF") 07-5, "Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock" ("EITF 07-5"). EITF 07-5 provides framework for determining whether an instrument is indexed to an entity's own stock. EITF 07-5 is effective for fiscal years beginning after December 15, 2008. The Company is currently evaluating the impact of the adoption of EITF 07-5 on its financial position and results of operations.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of Accounting Research Bulletin ARB No. 51, Consolidated Financial Statements (SFAS No. 160). SFAS No. 160 requires (i) that non-controlling (minority) interests be reported as a component of stockholders' equity, (ii) that net income attributable to the parent and to the non-controlling interest be separately identified in the consolidated statement of operations, (iii) that changes in a parent's ownership interest while the parent retains its controlling interest be accounted for as equity transactions, (iv) that any retained non-controlling equity investment upon the deconsolidation of a subsidiary be initially measured at fair value and, (v) that sufficient disclosures are provided that clearly identify and distinguish between the interests of the parent and the interests of the non-controlling owners. SFAS No. 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. We adopted SFAS No. 160 for our fiscal year beginning January 1, 2009, and the adoption did not have any impact on our consolidated financial position, results of operations and cash flows.

In April 2009, the FASB issued Staff Position No. FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments (FSP FAS 107-1 and APB 28-1). FSP FAS 107-1 and APB 28-1 extends the disclosure requirements of SFAS 107 to interim period financial statements, in addition to the existing requirements for annual periods and reiterates SFAS 107's requirement to disclose the methods and significant assumptions used to estimate fair value. FSP FAS 107-1 and APB 28-1 is effective for our interim and annual periods commencing with our June 30, 2009 consolidated financial statements and will be applied on a prospective basis. We believe the adoption of FSP FAS 107-1 and APB 28-1 will not have a material impact on consolidated financial position, results of operations and cash flows.

In April 2009, the FASB issued SFAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments (SFAS 107-1). SFAS 107-1 amends FASB No. 107, Disclosures about Fair Value of Financial Instruments, to require disclosures about fair value of financial instruments for interim reporting periods of publicly traded companies as well as in annual financial statements. SFAS also amends APB Opinion No. 28, Interim Financial Reporting, to require those disclosures in summarized financial information at interim reporting periods. SFAS 107-1 is effective for interim and annual reporting periods ending after June 15, 2009. We do not believe the adoption of this standard will have a material impact on our consolidated financial position, results of operations and cash flows.

Edgar Filing: FONAR CORP - Form 10-Q

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassifications did not have any effect on reported consolidated net losses for any periods presented.

NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE

Medical Receivables

The Company was assigned medical receivables valued at \$11,775,000, in connection with the satisfaction of the management fees and termination fees related to a Termination and Replacement Agreement dated May 23, 2005. The balance of the net medical receivables as of March 31, 2009 was \$555,000. As of March 31, 2009 and June 30, 2008, the Company recorded an allowance for doubtful accounts of \$1,221,500 and \$769,000, respectively, on these receivables.

Accounts Receivable and Management Fee Receivable

Receivables, net is comprised of the following at March 31, 2009:
(000's Omitted)

	Gross Receivable -----	Allowance for doubtful accounts -----	Net -----
Receivables from equipment sales and service contracts	\$ 6,773 =====	\$ 1,567 =====	\$ 5,206 =====
Receivables from equipment sales and service contracts- related parties	\$ 1,238 =====	\$ 619 =====	\$ 619 =====
Management fee receivables	\$ 8,369 =====	\$ 4,318 =====	\$ 4,051 =====
Management fee receivables from related medical practices ("PC's")	\$ 3,858 =====	\$ 2,378 =====	\$ 1,480 =====

The Company's customers are concentrated in the healthcare industry.

The Company's receivables from the related and non-related professional corporations (PC's) substantially consists of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC's of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations.

As of June 22, 2007, an unrelated third party purchased the stock of the professional corporations owning the eight New York sites managed by the Company, previously owned by Dr. Raymond V. Damadian, the President, Chairman of the Board and principal stockholder of Fonar. In connection with the sale, new

Edgar Filing: FONAR CORP - Form 10-Q

management agreements were substituted for the existing management agreements, providing, however, for the same management services. The fees starting in fiscal 2008, however, are currently fixed monthly fees in amounts ranging from \$45,000 to \$125,000 per month. Dr. Damadian still owns the four MRI facilities in Georgia and Florida managed by the Company. No MRI facilities or other medical facilities are owned by the Company.

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE (CONTINUED)

Collection by the Company of its management fee receivables may be impaired by the uncollectibility of the PC's medical fees from third party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 48% and 44% of the PC's net revenues for both the nine months ended March 31, 2009 and 2008, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for doubtful accounts and contractual allowances. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management's expectations.

Net revenues from management and other fees charged to the related P.C.'s accounted for approximately 7.4% and 10.0% of the consolidated net revenues for the nine months ended March 31, 2009 and 2008, respectively. Product sales and service repair fees from related parties amounted to approximately 3.3% and 2.9% of consolidated net revenues for the nine months ended March 31, 2009 and 2008 respectively.

HMCA entered into a management agreement in September 2007 with Integrity Healthcare Management Inc ("Integrity"). Under the terms of the agreement, Integrity provided the billings and collections for HMCA's facilities as well as assist in the management of the facilities. Integrity was to receive as compensation an annual fee equal to one-half of the increase in the consolidated cash flow of HMCA and the facilities over the period from July 1, 2006 through June 30, 2007. The original term of the agreement was one year with an automatic year to year renewal, but may be terminated by either party without cause at the end of any year. During June 2008, HMCA terminated the agreement and no management fees were earned by Integrity. Integrity is a subsidiary of Health Diagnostics, LLC. The director of Health Diagnostics, LLC, Timothy Damadian, is a son of the President and Chief Executive Officer of Fonar, Dr. Raymond Damadian. Commencing with June 2008, however, the Company hired Health Diagnostics, LLC, the parent company of Integrity, to perform all billing and collection procedures on its behalf. The Company has agreed to pay 6% of all adjusted deposits for these services. Amounts charged to HMCA during the nine months ended March 31, 2009 under this agreement totaled \$794,006. HMCA terminated the billing and collection agreement as of April 30, 2009.

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009

Edgar Filing: FONAR CORP - Form 10-Q

(UNAUDITED)

NOTE 3 - MEDICAL RECEIVABLES, ACCOUNTS RECEIVABLE AND MANAGEMENT FEE RECEIVABLE (CONTINUED)

Unaudited Financial Information of Unconsolidated Managed Medical Practices

Audited financial information related to the unconsolidated related and unrelated P.C.'s managed by the Company is not available. Substantially all of these medical practices' books and records are maintained on a cash basis, they depreciate their equipment on an accelerated tax basis and have a December 31 year end.

Summarized statement of operations data for the three months ended March 31, 2009 and 2008 related to the unconsolidated medical practices managed by the Company is as follows:

(000's omitted) (Income Tax-Cash Basis)		
	For the three months ended March 31,	
	2009	2008
Patient Revenue - Net	\$ 3,936	\$ 4,603
Income from Operations	\$ 104	\$ 172
Net Income	\$ 87	\$ 55

Summarized statement of operations data for the nine months ended March 31, 2009 and 2008 related to the unconsolidated medical practices managed by the Company is as follows:

(000's omitted) (Income Tax-Cash Basis)		
	For the nine months ended March 31,	
	2009	2008
Patient Revenue - Net	\$11,874	\$12,955
Loss from Operations	\$ (31)	\$ (306)
Net Loss	\$ (83)	\$ (698)

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 4 - INVENTORIES

Inventories included in the accompanying condensed consolidated balance sheet consist of the following:

(000's omitted)	
March 31,	June 30,
2009	2008
-----	-----

Edgar Filing: FONAR CORP - Form 10-Q

Purchased parts, components and supplies	\$ 2,587	\$ 1,847
Work-in-process	1,206	1,409
	-----	-----
	\$ 3,793	\$ 3,256
	=====	=====

NOTE 5 - COSTS AND ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER ADVANCES

- 1) Information relating to uncompleted contracts as of March 31, 2009 is as follows: (000's omitted)

Costs incurred on uncompleted contracts	\$ 8,444
Estimated earnings	5,343

	13,787
Less: Billings to date	18,392

	\$ (4,605)
	=====

Included in the accompanying condensed consolidated balance sheet at March 31, 2009 under the following captions:

Costs and estimated earnings in excess of billings on uncompleted contracts	528
Less: Billings in excess of costs and estimated earnings on uncompleted contracts	5,133

	\$ (4,605)
	=====

- 2) Customer advances consist of the following as of March 31, 2009:

	Total	Related Party	Other
	-----	-----	-----
Total Advances	\$ 27,117	\$ 854	\$ 26,263
Less: Advances on contracts under construction	18,392	-	18,392
	-----	-----	-----
	\$ 8,725	\$ 854	\$ 7,871
	=====	=====	=====

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 6 - OTHER CURRENT LIABILITIES

Other current liabilities in the accompanying condensed consolidated balance sheet consist of the following:

Edgar Filing: FONAR CORP - Form 10-Q

(000's omitted)

	March 31, 2009	June 30, 2008
Royalties	\$ 623	\$ 623
Accrued salaries, commissions and payroll taxes	1,073	901
Accrued interest	793	876
Litigation accruals	193	193
Sales tax payable	2,687	2,544
Legal and other professional fees	596	634
Accounting fees	360	503
Insurance premiums	177	410
Penalty - Sales tax	657	632
Penalty - 401k plan (see Note 11)	250	250
Other	636	750
	<u>\$ 8,045</u>	<u>\$ 8,316</u>

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 7 - SALE OF CONSOLIDATED SUBSIDIARY AND INVESTMENT

Sale of Consolidated Subsidiary

On September 30, 2008, the Company sold its 92.3% interest (to a related party) in an entity that provided management services to a diagnostic center in Bensonhurst, NY. The Company continues to manage other diagnostic centers in the New York region.

The related third party purchased all assets and assumed all liabilities of the diagnostic center which included cash, the management fee receivable, furniture and fixtures and other miscellaneous assets. The purchase price for the 92.3% interest was \$2,307,500 all of which was paid in cash at the time of closing.

The following is the calculation of the gain on sale of the 92.3% interest in a consolidated subsidiary:

(000's omitted)

Selling Price - Net cash paid:	\$ 2,307
Assets and liabilities sold:	
Cash	\$ 14
Management fee receivable -net	917
Property and equipment - net	1
Other assets	34
Accounts payable	(16)
Minority interest	(91)
Subtotal	859
Gain on sale of consolidated subsidiary	<u>\$ 1,448</u>

Edgar Filing: FONAR CORP - Form 10-Q

=====

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 7 - SALE OF CONSOLIDATED SUBSIDIARY AND SALE OF INVESTMENT (CONTINUED)

Sale of Consolidated Subsidiary (Continued)

On July 31, 2007, the Company sold its 50% interest (to an unrelated third party) in an entity that provided management services to a diagnostic center in Orlando, FL. The Company continues to manage other diagnostic centers in the Florida region.

The unrelated third party purchased all assets and assumed all liabilities of the diagnostic center which included cash, the management fee receivable, furniture and fixtures and other miscellaneous assets. The purchase price for the 50% interest was \$4,500,000 and after closing costs the amount received was \$4,257,000.

The following is the calculation of the gain on sale of the 50% interest in a consolidated subsidiary:

	(000's omitted)	
Selling Price:		\$ 4,500
Less: Closing costs		(243)
Selling Price - Net cash paid :		4,257
Assets sold:		
Cash	\$ 114	
Management fee receivable	1,166	
Property and equipment - net	23	
Other assets	15	
Minority interest	(456)	
Subtotal		862

Gain on sale of consolidated subsidiary		\$ 3,395
		=====

Sale of Investment

On July 31, 2007, the Company sold its 20% equity interest in an unconsolidated entity (management company for a diagnostic center) to an unrelated third party. The selling price was \$629,195. The Company realized a gain on the sale of the equity interest of \$571,161.

The gain was calculated as follows:

	(000's omitted)	
Selling Price:	\$ 629	
Less: Closing costs	(58)	
Selling Price - Net cash paid	571	
Cost Basis	-	

Edgar Filing: FONAR CORP - Form 10-Q

Gain on sale of investment	\$ 571
	=====

FONAR CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2009 (UNAUDITED)

NOTE 8 - SEGMENT AND RELATED INFORMATION

The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company's 10-K as of June 30, 2008. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations.

Summarized financial information concerning the Company's reportable segments is shown in the following table:

(000's omitted)

	Medical Equipment -----	Management of Diagnostic Imaging Centers -----	Totals -----
For the three months ended March 31, 2009:			
Net revenues from external customers	\$ 8,778	\$ 2,478	\$ 11,256
Inter-segment net revenues	\$ 245	\$ -	\$ 245
Income from operations	\$ 816	\$ (54)	\$ 762
Depreciation and amortization	\$ 262	\$ 168	\$ 430
Capital expenditures	\$ 190	\$ 12	\$ 202

For the three months ended March 31, 2008:

Net revenues from external customers	\$ 5,133	\$ 2,938	\$ 8,071
Inter-segment net revenues	\$ 208	\$ -	\$ 208
Loss from operations	\$ (2,510)	\$ (211)	\$ (2,721)
Depreciation and amortization	\$ 353	\$ 230	\$ 583
Capital expenditures	\$ 353	\$ 28	\$ 381

For the nine months ended March 31, 2009:

Net revenues from external customers	\$ 21,632	\$ 7,699	\$ 29,331
Inter-segment net revenues	\$ 762	\$ -	\$ 762
Income (Loss) from operations	\$ 207	\$ (593)	\$ (386)
Depreciation and amortization	\$ 793	\$ 504	\$ 1,297
Capital expenditures	\$ 588	\$ 16	\$ 604
Identifiable assets	\$ 17,630	\$ 12,003	\$ 29,633

For the nine months ended March 31, 2008:

Net revenues from external customers	\$18,328	\$ 9,093	\$ 27,421
Inter-segment net revenues	\$ 662	\$ -	\$ 662
Loss from operations	\$ (9,944)	\$ (759)	\$ (10,703)
Depreciation and amortization	\$ 1,032	\$ 695	\$ 1,727

Edgar Filing: FONAR CORP - Form 10-Q

Capital expenditures	\$ 793	\$ 102	\$ 895
Identifiable assets - June 30, 2008	\$ 19,203	\$ 16,022	\$ 35,225

FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2009
(UNAUDITED)

NOTE 9 - SUPPLEMENTAL CASH FLOW INFORMATION

During the nine months ended March 31, 2009 and March 31, 2008, the Company paid \$278,000 and \$178,000 for interest, respectively.

The Company paid \$36,000 and \$0 for income taxes during the nine months ended March 31, 2009 and 2008, respectively.

NOTE 10 - COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company.

Other Matters

In March 2007, the Company and New York State taxing authorities conducted a conference to discuss a sales tax matter to determine if certain sales transactions are subject to sales tax withholdings. In fiscal 2007, the Company recorded a provision of \$250,000 to cover any potential tax liability including interest. This matter was settled in May of 2009 with no payment required by the Company. The Company will reverse the accrual for this matter in the quarter ended June 30, 2009.

The Company is also delinquent in filing sales tax returns for certain states, for which the Company has transacted business. As of March 31, 2009, the Company has recorded tax obligations of approximately \$2,025,000 plus interest and penalties of approximately \$1,310,000. The Company is in the process of determining the regulatory requirements in order to become compliant.

The Company has determined they may not be in compliance with the Department of Labor and Internal Revenue Service regulations concerning the requirements to file Form 5500 to report activity of its 401(k) Employee Benefit Plan. The filings do not require the Company to pay tax, however they may be subject to penalty for non-compliance. The Company has recorded provisions for any potential penalties totaling \$250,000. Such amount is the Company's best estimate of potential penalties. Management is unable to determine the outcome of this uncertainty. The Company has engaged outside counsel to handle such matters to determine the necessary requirements to ensure compliance. Such non-compliance could impact the eligibility of the plan.

FONAR CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2009

Edgar Filing: FONAR CORP - Form 10-Q

(UNAUDITED)

NOTE 10 - COMMITMENTS AND CONTINGENCIES Continued

NASDAQ Notice of Non-compliance

The Company's stockholder's deficiency was \$4.2 million as of June 30, 2008 and \$3.0 million as of March 31, 2009. NASDAQ had granted the Company an extension to April 9, 2009 to evidence compliance with the minimum stockholders' equity requirement or minimum net income requirement for continued listing on the NASDAQ Capital Market. Although the Company was unable to raise the equity financing necessary to do so, the Company's common stock continues to be listed pending its appeal to the NASDAQ Listing and Hearing Review Council requesting an extension until after the filing of our Form 10-K for fiscal 2009 to demonstrate compliance with one or more of the continued listing requirements.

NOTE 11 - NOTES RECEIVABLE

On August 8, 2008, the Company signed a modification agreement with regards to the Asset Purchase Agreement with Health Plus. Under the modification agreement Health Plus made a \$2,000,000 principal payment on the promissory note in exchange for a discount on the original note of \$1,000,000.

The original promissory note ("Note") was modified to \$2,378,130 payable in 60 consecutive months in equal installments of principal and interest of \$47,090. The Note is secured by a first lien on all of the assets of Health Plus, including its accounts receivable and is subject to prepayment provisions to the extent Health Plus resells all or part of the assets and business or utilizes the assets sold as collateral in any debt financing. The note provides for interest at 7% per annum. The Company recorded a change to earnings representing the net discount on this note of \$658,351 on this transaction during the quarter ended June 30, 2008.

NOTE 12 - LIFE INSURANCE

During the three months ended March 31, 2009, the Company borrowed \$1.3 million against the cash surrender value of a whole life insurance policy on the life of the Company's Chief Executive Officer.

NOTE 13 - LICENSE FEES AND ROYALTIES

In July 2000, the Company entered into a non-exclusive sales representative agreement with an unrelated third party. The agreement requires the third party to sell at least two Fonar MRI scanners or if it does not, pay an amount equal to the Company's gross margin on the unsold MRI scanner(s). The third party has not sold any scanners in the past two contract years. The Company received the gross margin payment on two scanners of approximately \$1.2 million in November 2007 and is shown in the Company's condensed consolidated statements of operations as revenue, license fees and royalties for the nine months ended March 31, 2008. The Company received the gross margin payment on one scanner of approximately \$585,000 in November 2008 and applied a previously received deposit for two other scanners for a total of \$1.8 million shown as license fees and royalties for the nine months ended March 31, 2009.

Edgar Filing: FONAR CORP - Form 10-Q

FONAR CORPORATION AND SUBSIDIARIES

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

For the nine month period ended March 31, 2009, we reported net income of \$1.1 million on revenues of \$29.3 million as compared to net loss of \$6.7 million on revenues of \$27.4 million for the nine month period ended March 31, 2008.

For the three month period ended March 31, 2009, we reported net income of \$730,000 on revenues of \$11.3 million as compared to net loss of \$2.7 million on revenues of \$8.1 million for the three month period ended March 31, 2008.

Overall, our revenues increased 7.0% from \$27.4 million for the first nine months of fiscal 2008 to \$29.3 million for the first nine months of fiscal 2009. Most significantly, revenues from product sales increased 33.9%, from \$8.9 million for the first nine months of fiscal 2008 to \$12.0 million for the first nine months of fiscal 2009. This sharp increase resulted from the Company's increased production activity in the filling of orders for our MRI scanners.

Due to the increase in our revenues and a reduction of cost and expenses, our operating loss for the nine months ended March 31, 2009 was reduced as compared to the nine months ended March 31, 2008 (a \$386,000 operating loss for the first nine months of fiscal 2009 as compared to a \$10.7 million operating loss for the first nine months of fiscal 2008). The decrease in the operating loss was principally due to a decrease of 22.1% in our total costs and expenses, from \$38.1 million for the first nine months of fiscal 2008 to \$29.7 million for the first nine months of fiscal 2009. In order to reduce our net losses and demands on our cash and other liquid reserves, we instituted an aggressive program of cost cutting at the end of fiscal 2008 and the beginning of fiscal 2009. Costs and expenses were reduced in most categories but most significantly in our selling general and administrative expenses. Overall, there was a reduction of our selling, general and administrative expenses of 36%, from \$15.5 million in the first nine months of fiscal 2008 to \$10.0 million in the first nine months of fiscal 2009, resulting directly from our cost cutting program.

In addition to the success of our cost cutting program in improving our operating performance, we also realized a gain on the sale in September 2008 of our 92.3% interest in a consolidated entity. We received proceeds of approximately \$2.3 million and recognized a gain of approximately \$1.4 million, which also improved our liquidity. The entity was engaged in the business of managing a MRI facility. The principal reason, however, for our net income for the first nine months of fiscal 2009 of \$1.1 million as compared to our net loss for the first nine months of fiscal 2008 of \$6.7 million, was due to the improvement in our operations.

We also are monitoring the performance of our existing users in order to establish teams to assist underperforming customers improve their scan volume. In addition, we have held seminars to assist customers and the MRI Facilities managed by HMCA in their marketing efforts and are in the process of developing a web site to assist our customers in their marketing efforts.

We implemented an aggressive program of cost cutting measures at the end of fiscal 2008 and the beginning of fiscal 2009. These measures include consolidating HMCA's office space with Fonar's office space, reductions in the size of our workforce, compensation and benefits, as well as across the board reduction of expenses.

Forward Looking Statements

Edgar Filing: FONAR CORP - Form 10-Q

Certain statements made in this Quarterly Report on Form 10-Q are "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of Management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that our assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statement included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved.

Results of Operations

We operate in two industry segments: the manufacture and servicing of medical (MRI) equipment, our traditional business which is conducted directly by Fonar, and diagnostic facilities management services, which is conducted through Fonar's wholly-owned subsidiary, Health Management Corporation of America, which we also refer to as HMCA.

Trends in the third quarter of fiscal 2009 include an increase in product sales revenues, a decrease in service and repair fees, and management fees, as well as a decrease in our total costs and expenses, in particular in our selling, general and administrative expenses. We will continue to focus on our marketing efforts to improve sales performance in fiscal 2009. In addition, we will monitor our cost cutting program and will continue to reduce costs as necessary.

For the three month period ended March 31, 2009, as compared to the three month period ended March 31, 2008, overall revenues from MRI product sales increased 162% (\$6.2 million compared to \$2.3 million).

For the nine month period ended March 31, 2009, as compared to the nine month period ended March 31, 2008, overall revenues from MRI product sales increased 33.9% (\$12.0 million compared to \$8.9 million).

Service revenues for the three month period ended March 31, 2009, as compared to the three month period ended March 31, 2008 decreased by 5.9% (\$2.6 million compared to \$2.8 million). Unrelated party service and repair fees decreased by 8.9% (\$2.3 million compared to \$2.5 million) and related party service and repair fees increased by 22.6% (\$331,000 compared to \$270,000). The reason for the decrease in unrelated party service and repair fees was attributable to several customers discontinuing operations because of economic conditions. We anticipate that there will be increases in service revenues as warranties on installed scanners expire over time.

Service revenues for the nine month period ended March 31, 2009, as compared to the nine month period ended March 31, 2008 decreased by 4.0% (\$7.9 million compared to \$8.2 million). Unrelated party service and repair fees decreased by 6.8% (\$6.9 million compared to \$7.4 million) and related party service and repair fees increased by 22.9% (\$966,000 compared to \$786,000).

Edgar Filing: FONAR CORP - Form 10-Q

There were approximately \$3.4 million in foreign revenues for the first nine months of fiscal 2009 as compared to approximately \$628,000 in foreign revenues for the first nine months of fiscal 2008, representing an increase in foreign revenues of 434%. The Company is making a concerted effort to increase foreign sales, most recently through its foreign distributors.

Overall, for the first nine months of fiscal 2009, revenues for the medical equipment segment increased by 18.0% to \$21.6 million from \$18.3 million for the first nine months of fiscal 2008. The revenues generated by HMCA decreased, by 15.3%, to \$7.7 million for the first nine months of fiscal 2009 as compared to \$9.1 million for the first nine months of fiscal 2008.

We recognize MRI scanner sales revenues on the "percentage of completion" basis, which means the revenues are recognized as the scanner is manufactured. Revenues recognized in a particular quarter do not necessarily reflect new orders or progress payments made by customers in that quarter. We build the scanner as the customer meets certain benchmarks in its site preparation in order to minimize the time lag between incurring costs of manufacturing and our receipt of the cash progress payments from the customer which are due upon delivery. Consequently, there can be a disparity between the revenues recognized in a fiscal period and the number of product sales. Generally, the recognized revenue results from revenues from a scanner sale are recognized in a fiscal quarter or quarters following the quarter in which the sale was made.

Costs related to product sales increased by 48.6% from \$2.2 million in the third quarter of fiscal 2008 to \$3.3 million in the third quarter of 2009, reflecting an increase in product sales revenues. The increase in costs by 48.6% was substantially less than the corresponding increase in MRI product sales revenues of 162%, however, primarily because we were able to both procure parts and components at lower costs and use parts and components in inventory having a lower cost basis. Costs related to providing service decreased by 22.1% from \$1.3 million in the third quarter of fiscal 2008 to \$1.0 million in fiscal 2009. The increase in product sales revenues resulted primarily from the Company's progress in filling its backlog of orders.

Notwithstanding the increase in revenues from MRI product sales, costs related to product sales decreased by 11.4% from \$8.6 million in the first nine months of fiscal 2008 to \$7.6 million in the first nine months of 2009 because of our lower cost basis for parts and components. Costs related to providing service decreased by 21.7% from \$3.9 million in the first nine months of fiscal 2008 to \$3.1 million in fiscal 2009.

Costs related to providing service and repairs decreased by 22.1% for the third quarter of fiscal 2009 compared to the third quarter of fiscal 2008 and by 21.7% for the first nine months of fiscal 2009 compared to the first nine months of fiscal 2008. We believe that an important factor in keeping service costs down is our ability to monitor the performance of customers' scanners from our facilities in Melville, New York, on a daily basis and to detect and repair any irregularities before more serious problems result. We also believe the low cost of providing service reflects the high quality of our products.

Overall, the operating results for our medical equipment segment improved to an operating income of \$207,000 for the first nine months of fiscal 2009 as compared to an operating loss of \$9.9 million for the first nine months of fiscal 2008. This improvement resulted from an increase in product sales revenues and decreases in costs related to sales, research and development and, most significantly, selling, general and administrative expenses. The decrease in costs related to sales resulted from our ability to procure parts and components at lower costs and to use parts and components in inventory having a lower cost basis. The decrease in research and development expenditures, and selling, general and administrative expenses, resulted from our program of cost cutting measures, which included consolidating HMCA's office space with Fonar's

Edgar Filing: FONAR CORP - Form 10-Q

office space, reductions in the size of our workforce, compensation and benefits, as well as an across the board reduction of expenses.

HMCA revenues decreased in the third quarter of fiscal 2009 by 15.7% to \$2.5 million from \$2.9 million for the third quarter of fiscal 2008, and by 15.3% to \$7.7 million for the first nine months of fiscal 2009 from \$9.1 million for the first nine months of fiscal 2008, primarily because of the sale of its 92.3% interest in a previously consolidated entity in September 2008. We now manage ten sites, nine of which are equipped with FONAR UPRIGHT(R) MRI scanners. HMCA experienced an operating loss of \$593,000 for the first nine months of fiscal 2009 compared to operating loss of \$759,000 for the first nine months of fiscal 2008.

HMCA cost of revenues decreased to \$1.7 million for the third quarter of fiscal 2009 as compared to \$2.1 million for the third quarter of fiscal 2008. HMCA cost of revenues for the first nine months of fiscal 2009 decreased to \$5.4 million as compared to \$6.1 million for the first nine months of fiscal 2008. The decrease in HMCA's cost of revenues was primarily the result of managing one less scanning center as a result of the sale of HMCA's 92.3% interest in a previously consolidated entity in September, 2008.

HMCA entered into an agreement in September, 2007 with Integrity Healthcare Management, Inc. ("Integrity"), which is a wholly-owned subsidiary of Health Diagnostics, LLC. Under the terms of the agreement, Integrity supervised and directed HMCA and the management of the facilities including the performance of billing and collections services. The existing management agreements between the facilities and HMCA remained in place. Integrity was entitled to compensation of an annual fee equal to one-half of the increase in the consolidated cash flow of HMCA and the facilities over the period from July 1, 2006 through June 30, 2007. This agreement was terminated as of the end of June 2008.

Commencing upon the termination of this agreement, we hired Health Diagnostics, LLC, the parent company of Integrity, to perform all billing and collection procedures for HMCA's clients on HMCA's behalf. HMCA agreed to pay 6% of all adjusted deposits for these services. This agreement was terminated as of April 30, 2009, as HMCA sought to cut expenses and exercise direct control of the billing and collection of its clients' accounts.

The increase in our total net revenues of 39.5% from \$8.1 million in the third quarter of fiscal 2008 to \$11.3 million in the third quarter of fiscal 2009, was accompanied by a decrease of 2.8% in total costs and expenses from \$10.8 million in the third quarter of fiscal 2008 compared to \$10.5 million in the third quarter of fiscal 2009. As a result, our income (loss) from operations changed from a loss of \$2.7 million in the third quarter of fiscal 2008 to an operating profit of \$762,000 in the third quarter of fiscal 2009.

For the first nine months of fiscal 2009 the consolidated revenues increased by 7.0% to \$29.3 from \$27.4 million for the first nine months of fiscal 2008 while the total costs and expenses decreased by 22.1% to \$29.7 million for the first nine months of fiscal 2009 from \$38.1 million for the first nine months of fiscal 2008. Our operating loss decreased from \$10.7 million in the first nine months of fiscal 2008 to \$386,000 in the first nine months of fiscal 2009.

Selling, general and administrative expenses decreased by 36.0% to \$10.0 million in the first nine months of fiscal 2009 from \$15.5 million in the first nine months of fiscal 2008, largely as a result of our aggressive cost cutting measures. There was no compensatory element of stock issuances, which is included in selling, general and administrative expenses, in the first nine months of fiscal 2009 or 2008.

Research and development expenses decreased by 27% to \$2.7 million for the

Edgar Filing: FONAR CORP - Form 10-Q

first nine months of fiscal 2009 as compared to \$3.7 million for the first nine months of fiscal 2008.

Interest expense in the first nine months of fiscal 2009 decreased by 46.7% to \$193,000 from \$362,000 for the first nine months of fiscal 2008 because of the repayment of existing debt.

Inventories increased by 16.5% to \$3.8 million at March 31, 2009 as compared to \$3.3 million at June 30, 2008 representing the purchase of raw materials and components in our inventory to fill orders.

Management fee and medical receivables decreased by 20.3% to \$6.1 million at March 31, 2009 from \$7.6 million at June 30, 2008, primarily due to collections on the Company's management fee receivables and the sale of a 92.3% interest of a consolidated entity in September 2008, which included the receivables of such entity.

The overall trends reflected in the results of operations for the first nine months of fiscal 2009 are an increase in revenues from product sales, as compared to the first nine months of fiscal 2008 (\$12.0 million for the first nine months of fiscal 2009 as compared to \$8.9 million for the first nine months of fiscal 2008), and an increase in MRI equipment segment revenues relative to HMCA revenues (\$21.6 million or 73.8% from the MRI equipment segment as compared to \$7.7 million or 26.2% from HMCA, for the first nine months of fiscal 2009, as compared to \$18.3 million or 66.8% from the MRI equipment segment and \$9.1 million or 33.2%, from HMCA, for the first nine months of fiscal 2008). In addition, unrelated party sales constituted 100% of our medical equipment product sales for the first nine months of fiscal 2009 at \$12.0 million and for the first nine months of fiscal 2008 at \$8.9 million.

We are committed to continuing the improvement in our operating results we experienced in the first nine months in fiscal 2009. Nevertheless, factors beyond our control, such as the timing and rate of market growth which depend on economic conditions, including the availability of credit, payor reimbursement rates and policies, and unexpected expenditures or the timing of such expenditures, make it impossible to forecast future operating results. We believe we are pursuing the correct policies which should prove successful in improving the Company's operating results.

Our FONAR UPRIGHT(R) MRI, and Fonar-360(TM) MRI scanners, together with our works-in-progress, are intended to significantly improve our competitive position.

Our FONAR UPRIGHT(R) MRI scanner, which operates at 6000 gauss (.6 Tesla) field strength, allows patients to be scanned while standing, sitting, reclining and in multiple flexion and extension positions. It is common in visualizing the spine that abnormalities are visualized in some positions and not others. This enables surgical corrections that heretofore would be unaddressable for lack of visualizing the symptom causing the pathology. A floor-recessed elevator brings the patient to the height appropriate for the targeted image region. A custom-built adjustable bed will allow patients to sit or lie on their backs, sides or stomachs at any angle. Full-range-of-motion studies of the joints in virtually any direction are possible and another promising feature for sports injuries.

Recently, this capability of the FONAR UPRIGHT(R) technology has demonstrated its key value on patients with the Arnold-Chiari syndrome, which is believed to affect 200,000 to 500,000 Americans. In this syndrome, brain stem compression and subsequent severe neurological symptoms occur in these patients, when because of weakness in the support tissues within the skull, the brain stem descends and is compressed at the base of the skull in the foramen magnum, which is the circular bony opening at the base of the skull where the spinal cord

Edgar Filing: FONAR CORP - Form 10-Q

exits the skull. Conventional lie-down MRI scanners cannot make an adequate evaluation of the pathology since the patient's pathology is most visible and the symptoms most acute when the patient is scanned in the upright weight-bearing position.

The UPRIGHT(R) MRI has also demonstrated its value for patients suffering from scoliosis. Scoliosis patients have been typically subjected to routine x-ray exams for years and must be imaged upright for an adequate evaluation of their scoliosis. Because the patient must be standing for the exam, an x-ray machine has been the only modality that could provide that service. The UPRIGHT(R) MRI is the only MRI scanner which allows the patient to stand during the MRI exam. Fonar has developed a new RF receiver and scanning protocol that for the first time allows scoliosis patients to obtain diagnostic pictures of their spines without the risks of x-rays. A recent study by the National Cancer Institute (2000) of 5,466 women with scoliosis reported a 70% increase in breast cancer resulting from 24.7 chest x-rays these patients received on the average in the course of their scoliosis treatment. The UPRIGHT(R) MRI examination of scoliosis enables the needed imaging evaluation of the degree of spine scoliosis without exposing the patient to the risk of breast cancer from x-radiation. Currently scoliosis affects more than 3,000,000 American women.

In addition, the University of California, Los Angeles (UCLA) reported their results of their study of 1,302 patients utilizing the FONAR UPRIGHT(R) Multi-Position(TM) MRI at the 22nd Annual Meeting of the North American Spine Society on October 23, 2007. The UCLA study showed the superior ability of the Dynamic(TM) FONAR UPRIGHT(R) MRI to detect spine pathology, including spondylolisthesis, disc herniations and disc degeneration, as compared to visualizations of the spine produced by traditional single position static MRIs.

The UCLA study by MRI of 1,302 back pain patients when they were UPRIGHT(R) and examined in a full range of flexion and extension positions made possible by FONAR's new UPRIGHT(R) technology established that significant "misses" of pathology were occurring with static single position MRI imaging. At L4-5, the vertebral level responsible for 49.8% of lumbar disc herniations, 35.1% of the spondylolistheses (vertebral instabilities) visualized by Dynamic(TM) Multi-Position(TM) MRI were being missed by static single position MRI (510 patients). Since this vertebral segment is responsible for the majority of all disc herniations, the finding may reveal a significant cause of failed back surgeries. The UCLA study further showed the "miss-rate" of vertebral instabilities by static only MRI was even higher, 38.7%, at the L3-4 vertebral segment. Additionally the UCLA study showed that MRI examinations of the cervical spine that did not perform extension images of the neck "missed" disc bulges 23.75% of the time (163 patients).

The UCLA study further reported that they were able to quantitatively measure the dimensions of the central spinal canal with the "highest accuracy" using the FONAR UPRIGHT(R) Multi-Position(TM) MRI thereby enabling the extent of spinal canal stenosis that existed in patients to be measured. Spinal canal stenosis gives rise to the symptom complex intermittent neurogenic claudication manifest as debilitating pain in the back and lower extremities, weakness and difficulties in ambulation and leg paresthesias. Spinal canal stenosis is a spinal compression syndrome separate and distinct from the more common nerve compression syndrome of the spinal nerves as they exit the vertebral column through the bony neural foramen.

The FONAR UPRIGHT(R) MRI can also be useful for MRI directed emergency neuro-surgical procedures as the surgeon would have unhindered access to the patient's head when the patient is supine with no restrictions in the vertical direction. This easy-entry, mid-field-strength scanner could prove ideal for trauma centers where a quick MRI-screening within the first critical hour of treatment will greatly improve patients' chances for survival and optimize the extent of recovery.

Edgar Filing: FONAR CORP - Form 10-Q

The Fonar 360(TM) is an enlarged room sized magnet in which the floor, ceiling and walls of the scan room are part of the magnet frame. This is made possible by Fonar's patented Iron-Frame(TM) technology which allows the Company's engineers to control, contour and direct the magnet's lines of flux in the patient gap where wanted and almost none outside of the steel of the magnet where not wanted. Consequently, this scanner allows surgeons and other interventional physicians to walk inside the magnet and achieve 360 degree access to the patient to perform interventional procedures.

The Fonar 360(TM) is presently marketed as a diagnostic scanner and is sometimes referred to as the Open Sky(TM) MRI. In its Open Sky(TM) version, the Fonar 360(TM) serves as an open patient friendly scanner which allows 360 degree surgical access to the patient on the scanner bed. To optimize the patient-friendly character of the Open Sky(TM) MRI, the walls, floor, ceiling and magnet poles are decorated with landscape murals. The patient gap is twenty inches and the magnetic field strength, like that of the FONAR UPRIGHT(R), is 0.6 Tesla.

In the future, we expect the Fonar 360(TM) to function as an interventional MRI. The enlarged room sized magnet and 360o access to the patient afforded by the Fonar 360(TM) permits surgeons to walk into the magnet and perform surgical interventions on the patient under direct MR image guidance. Most importantly the exceptional quality of the MRI image and its capacity to exhibit tissue detail on the image, can then be obtained real time during the procedure to guide the interventionalist. Thus surgical instruments, needles, catheters, endoscopes and the like could be introduced directly into the human body and guided directly to a malignant lesion using the MRI image. The number of inoperable lesions could be significantly reduced by the availability of this new FONAR technology. Most importantly treatment can be carried directly to the target tissue.

The first Fonar 360(TM) MRI scanner, installed at the Oxford- Nuffield Orthopedic Center in Oxford, United Kingdom, is now carrying a full diagnostic imaging caseload. In addition, however, development of the works in progress Fonar 360(TM) MRI image guided interventional technology is actively progressing. Fonar software engineers have completed and installed their 2nd generation tracking software at Oxford-Nuffield which is designed to enable the surgeons to insert needles into the patient and accurately advance them, under direct visual image guidance, to the target tissue, such as a tumor, so that therapeutic agents can be injected.

The Company expects marked demand for its most commanding MRI products, the FONAR UPRIGHT(R) MRI and the Fonar 360(TM) because of their exceptional features in patient diagnosis and treatment. These scanners additionally provide improved image quality and higher imaging speed because of their higher field strength of .6 Tesla. The geometry of the FONAR UPRIGHT(R) MRI as compared to a single coil, or multiple coils on only one axis and its transverse magnetic field enables the use of two detector rf coils operating in quadrature which increases the FONAR UPRIGHT(R) MRI signal to noise ratio by 40%, providing a signal to noise ratio equal to a .84T recumbent only MRI scanner.

Liquidity and Capital Resources

Cash, cash equivalents and marketable securities decreased from \$2.4 million at June 30, 2008 to \$1.6 million at March 31, 2009. Marketable securities approximated \$18,000 as of March 31, 2009, as compared to \$1.1 million at June 30, 2008.

Cash used in operating activities for the first nine months of fiscal 2009 was \$5.7 million. Cash used in operating activities was attributable to a decrease in customer advances of \$5.6 million, a decrease in billings in excess

Edgar Filing: FONAR CORP - Form 10-Q

of costs and estimated earnings on uncompleted contracts of \$641,000 and an increase in accounts, management fee and medical receivables of \$1.1 million offset by a decrease in notes receivable of \$385,000 and the net income of \$1.1 million.

Cash provided by investing activities for the first nine months of fiscal 2009 was \$6.1

million. The principal source of cash from investing activities during the first nine months of fiscal 2009 consisted of proceeds from the sale of a consolidated subsidiary of \$2.3 million, proceeds of \$2.0 million from the prepayment by a debtor of a portion of a note receivable and sale of marketable securities of \$1.1 million, offset by capitalized software and patent costs of \$584,000.

Cash used in financing activities for the first nine months of fiscal 2009 was \$141,000. The principal uses of cash in financing activities during the first nine months of fiscal 2009 consisted of repayment of principal on long-term debt and capital lease obligations of \$243,000, repayment of notes receivable from employee stockholders of \$125,000 and distributions to holders of minority interests of \$23,000.

The Company's contractual obligations and the periods in which they are scheduled to become due are set forth in the following table:

Contractual Obligation	Total	Due in less Than 1 year	Due in 2-3 years	Due in 4-5 years	Due after 5 years
-----	-----	-----	-----	-----	-----
Long-term debt	\$ 545	\$ 22	\$ --	\$ --	\$ 523
Capital lease Obligations	342	119	223	--	--
Operating leases	11,512	1,731	3,732	3,517	2,532
-----	-----	-----	-----	-----	-----
Total cash Obligations	\$ 12,399	\$ 1,872	\$ 3,955	\$ 3,517	\$ 3,055
	=====	=====	=====	=====	=====

Total liabilities decreased by 17.1% to \$32.6 million at March 31, 2009 from \$39.3 million at June 30, 2008. We experienced an decrease in long-term debt and capital leases from \$757,000 at June 30, 2008 to \$746,000 at March 31, 2009 and a decrease in accounts payable from \$4.0 million at June 30, 2008 to \$3.7 million at March 31, 2009, along with a decrease in billings in excess of costs and estimated earnings on uncompleted contracts from \$5.8 million at June 30, 2008 to \$5.1 million at March 31, 2009, and a decrease in customer advances from \$14.3 million at June 30, 2008 to \$8.7 million at March 31, 2009. Unearned revenue on service contracts increased from \$5.2 million at June 30, 2008 to \$5.7 million at March 31, 2009.

As of March 31, 2009, the total of \$8.0 million in other current liabilities included primarily accrued salaries and payroll taxes of \$1.1 million, accrued interest of \$792,000, accrued royalties of \$623,000 and excise and sales taxes of \$2.7 million.

Our working capital deficit decreased from \$16.0 million as of June 30, 2008 to \$12.5 million as of March 31, 2009. This resulted from decrease in current liabilities (\$38.0 million at June 30, 2008 as compared to \$31.4 million at March 31, 2009, particularly a decrease in customer advances of \$5.6 million

Edgar Filing: FONAR CORP - Form 10-Q

(\$14.3 million at June 30, 2008 as compared to \$8.7 million at March 31, 2009), and a decrease in billings in excess of costs and estimated earnings on uncompleted contracts from \$5.8 million at June 30, 2008 to \$5.1 million at March 31, 2009; notwithstanding a decrease in current assets (\$22.0 million at June 30, 2008 compared to \$19.0 million at March 31, 2009) resulting primarily from a decrease in management fee receivable of \$881,000 (\$6.4 million at June 30, 2008 compared to \$5.5 million at March 31, 2009) and a decrease in current portion of notes receivable (\$2.5 million at June 30, 2008 as compared to \$509,000 at March 31, 2009), offset by an increase in accounts receivable of \$667,000 (\$5.2 million at June 30, 2008 as compared to \$5.8 million at March 31, 2009) and an increase in inventories of approximately \$537,000 (\$3.3 million at June 30, 2008 as compared to \$3.8 million at March 31, 2009).

Fonar has not committed to making additional capital expenditures in the 2009 fiscal year.

Our business plan calls for a continuing emphasis on providing our customers with enhanced equipment service and maintenance capabilities and delivering state-of-the-art, innovative and high quality equipment upgrades at competitive prices.

Our principal source of liquidity has been derived from revenues, as well as by the sale of marketable securities and cash provided by notes receivable. Also, in September 2008, the Company sold its 92.3% interest in a consolidated subsidiary and to a related third party and received proceeds of approximately \$2.3 million. In addition, during the third quarter of fiscal 2009, the Company received \$1.3 million from loans it made against the cash value of certain life insurance policies. At March 31, 2009, we had a working capital deficit of \$12.5 million. For the nine months ended March 31, 2009, we had a net income of \$1.1 million which included non-cash charges of \$2.4 million.

The Company is focusing on increased marketing campaigns and distribution programs to increase the demand for Fonar's products. Management anticipates that Fonar's capital resources will improve as Fonar's MRI scanner products gain wider market recognition and acceptance resulting in increased product sales. If we are not successful with our current marketing efforts to increase sales, then we could experience a shortfall in the cash necessary to sustain operations at their current levels.

Although sales levels remained weak in fiscal 2009, the Company has been profitable for two consecutive quarters; we are continuing to focus our efforts on increased marketing campaigns, in particular, by expanding Fonar's utilization of internet advertising as a vehicle for promoting our products and their unique features to the medical community and displaying the high quality visualization they achieve of pathologies that can not be seen by recumbent only MRI technology. Management anticipates that Fonar's capital resources will improve if Fonar's MRI scanner products gain wider market recognition and acceptance resulting in increased product sales. If we are not successful with our marketing efforts to increase sales and weak demand continues, we will experience a shortfall in cash over the next twelve months. If necessary, the Company will implement its plan to fund such a deficit which includes further reductions in operating expenses, sales of certain assets and loans from related parties together in an amount sufficient to continue as a going concern through March 31, 2010. Current economic credit conditions have contributed to a slowing business environment. Given such liquidity and credit constraints in the markets, the business may suffer, should the credit markets not improve in the near future. The direct impact of these conditions is not fully known. However, there can be no assurance that we would be able to secure additional funds if needed and that if such funds were available, whether the terms or conditions would be acceptable to us.

NASDAQ had granted Fonar an extension to April 9, 2009 to evidence

Edgar Filing: FONAR CORP - Form 10-Q

compliance with the minimum stockholders' equity requirement for continued listing on the NASDAQ Capital Market. Although Fonar was unable to raise the equity financing necessary to do so, Fonar's common stock continues to be listed pending its appeal to the NASDAQ Listing and Hearing Review Council. Fonar is requesting an extension until after the filing of its form 10-K for fiscal 2009 to demonstrate compliance with one or more of the continued listing requirements.

FONAR CORPORATION AND SUBSIDIARIES

Item 3. Quantitative and Qualitative Disclosures About Market Risk

The Company maintains its funds in liquid accounts. None of our investments are in fixed rate instruments.

All of our revenue, expense and capital purchasing activities are transacted in United States dollars.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures.

The Company maintains controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, the principal executive and acting principal financial officer of the Company concluded that disclosure controls and procedures were effective.

(b) Change in internal controls.

There have been no changes in our internal control over financial reporting that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

FONAR CORPORATION AND SUBSIDIARIES

PART II - OTHER INFORMATION

Item 1 - Legal Proceedings: There were no material changes in litigation for the first nine months of fiscal 2009.

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds: None

Item 3 - Defaults Upon Senior Securities: None

Item 4 - Submission of Matters to a Vote of Security Holders: None

Item 5 - Other Information: None

Item 6 - Exhibits and Reports on Form 8-K: Exhibit 31.1 Certification See Exhibits Exhibit 32.1 Certification See Exhibits

FONAR CORPORATION AND SUBSIDIARIES

Edgar Filing: FONAR CORP - Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

FONAR CORPORATION
(Registrant)

By: /s/ Raymond V. Damadian
Raymond V. Damadian
President & Chairman

Dated: May 18, 2009